[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100460887":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":42,"centralContacts":35,"locations":47,"responsibleParty":591,"collaborators":593,"id":597,"slug":598,"hasResults":599,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":35,"eligibilityCriteria":603,"healthyVolunteers":599,"sex":604,"minAge":605,"maxAge":35,"enrollmentInfo":606,"targetDuration":35,"studyType":609,"phases":610,"briefSummary":612,"conditions":613,"keywords":621,"overallStatus":50,"whyStopped":35,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":652},{"fullName":5,"class":6},"Genelux Corporation","INDUSTRY",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Olvi-Vec + Platinum-doublet & bevacizumab","EXPERIMENTAL","Olvi-Vec: A total of 2 consecutive days of intraperitoneal catheter infusions in Week 0\n\nPlatinum-doublet \\& bevacizumab (or biosimilar) administered beginning in Week 4 (preferred), but no later than Week 5",[13,14,15,16],"Biological: olvimulogene nanivacirepvec","Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin","Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin","Drug: Bevacizumab (or biosimilar)",{"label":18,"type":19,"description":20,"interventionNames":21},"Physician's Choice of Chemotherapy & bevacizumab","ACTIVE_COMPARATOR","Physician's Choice of chemotherapy \\& bevacizumab (or biosimilar) administered beginning in Week 0. Physician's Choice of chemotherapy includes either a single agent non-platinum chemotherapy, or as platinum chemotherapy is allowed as an option, a platinum-doublet (i.e., platinum agent combined with a non-platinum agent).",[14,15,16],[23,30,36,39],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","olvimulogene nanivacirepvec","Olvi-Vec is an engineered oncolytic vaccinia virus",[9],[29],"GL-ONC1 and GLV-1h68",{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Platinum chemotherapy: carboplatin (preferred) or cisplatin","Administered according to local practice",[9,18],null,{"type":31,"name":37,"description":33,"armGroupLabels":38,"otherNames":35},"Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin",[9,18],{"type":31,"name":40,"description":33,"armGroupLabels":41,"otherNames":35},"Bevacizumab (or biosimilar)",[9,18],[43],{"name":44,"affiliation":45,"role":46},"Robert W. Holloway, MD","AdventHealth Cancer Institute","PRINCIPAL_INVESTIGATOR",[48,70,91,107,126,142,157,173,193,210,227,246,267,283,300,313,333,348,369,386,401,418,434,450,470,492,512,529,546,562,574],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"The University of South Alabama, Mitchell Cancer Institute","RECRUITING","Mobile","Alabama","36604","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-88.04305,30.69436,{"lat":60,"lon":59},[63,68],{"name":64,"role":65,"phone":66,"phoneExt":35,"email":67},"Stefanie White","CONTACT","251-445-9834","swhite@southalabama.edu",{"name":69,"role":46,"phone":35,"phoneExt":35,"email":35},"Jennifer Pierce, MD",{"facility":71,"status":50,"city":72,"state":73,"zip":74,"country":54,"countryCode":55,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"University of Arizona Cancer Center","Tucson","Arizona","85719",{"type":57,"coordinates":76},[77,78],-110.92648,32.22174,{"lat":78,"lon":77},[81,85,89],{"name":82,"role":65,"phone":83,"phoneExt":35,"email":84},"Mitzi Miranda","520-626-0905","MMiranda@uacc.arizona.edu",{"name":86,"role":65,"phone":87,"phoneExt":35,"email":88},"Brianna Loughran","520-626-0939","bloughran@arizona.edu",{"name":90,"role":46,"phone":35,"phoneExt":35,"email":35},"Setsuko K. Chambers, MD",{"facility":92,"status":50,"city":93,"state":94,"zip":95,"country":54,"countryCode":55,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"City of Hope","Duarte","California","91010",{"type":57,"coordinates":97},[98,99],-117.97729,34.13945,{"lat":99,"lon":98},[102,106],{"name":103,"role":65,"phone":104,"phoneExt":35,"email":105},"Edward Wang, MD, PhD","877-467-3411","edwang@coh.org",{"name":103,"role":46,"phone":35,"phoneExt":35,"email":35},{"facility":108,"status":50,"city":109,"state":94,"zip":110,"country":54,"countryCode":55,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"UC San Diego Health - Moores Cancer Center","La Jolla","92093",{"type":57,"coordinates":112},[113,114],-117.2742,32.84727,{"lat":114,"lon":113},[117,121,123],{"name":118,"role":65,"phone":119,"phoneExt":35,"email":120},"Erika Peterson","858-822-5352","espeterson@health.ucsd.edu",{"name":122,"role":46,"phone":35,"phoneExt":35,"email":35},"Michael McHale, MD",{"name":124,"role":125,"phone":35,"phoneExt":35,"email":35},"Ramez Eskander, MD","SUB_INVESTIGATOR",{"facility":127,"status":50,"city":128,"state":94,"zip":129,"country":54,"countryCode":55,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Hoag Gynecologic Oncology","Newport Beach","92663",{"type":57,"coordinates":131},[132,133],-117.92895,33.61891,{"lat":133,"lon":132},[136,140],{"name":137,"role":65,"phone":138,"phoneExt":35,"email":139},"Esmeralda Martinez","949-764-5827","Esmeralda.Martinez@hoag.org",{"name":141,"role":46,"phone":35,"phoneExt":35,"email":35},"Alberto Mendivil, MD",{"facility":143,"status":50,"city":144,"state":94,"zip":145,"country":54,"countryCode":55,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"UCI Health Chao Family Comprehensive Cancer Center","Orange","92868",{"type":57,"coordinates":147},[148,149],-117.85311,33.78779,{"lat":149,"lon":148},[152,156],{"name":153,"role":65,"phone":154,"phoneExt":35,"email":155},"Krishnansu S. Tewari, MD","714-456-7971","ktewari@hs.uci.edu",{"name":153,"role":46,"phone":35,"phoneExt":35,"email":35},{"facility":45,"status":50,"city":158,"state":159,"zip":160,"country":54,"countryCode":55,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Orlando","Florida","32804",{"type":57,"coordinates":162},[163,164],-81.37924,28.53834,{"lat":164,"lon":163},[167,171],{"name":168,"role":65,"phone":169,"phoneExt":35,"email":170},"Karla Hernandez-Cruz","407-609-4437","Karla.Hernandezcruz@AdventHealth.com",{"name":172,"role":46,"phone":35,"phoneExt":35,"email":35},"Robert W Holloway, MD",{"facility":174,"status":50,"city":175,"state":159,"zip":176,"country":54,"countryCode":55,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Sarasota Memorial Research Institute","Sarasota","34239",{"type":57,"coordinates":178},[179,180],-82.53065,27.33643,{"lat":180,"lon":179},[183,187,191],{"name":184,"role":65,"phone":185,"phoneExt":35,"email":186},"Kim Lacy","941-917-6519","kim-lacy@smh.com",{"name":188,"role":65,"phone":189,"phoneExt":35,"email":190},"Amanda Kinker","941-917-1211","amanda-kinker@smh.com",{"name":192,"role":46,"phone":35,"phoneExt":35,"email":35},"Beverly Long, MD",{"facility":194,"status":50,"city":195,"state":196,"zip":197,"country":54,"countryCode":55,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"Emory University","Atlanta","Georgia","30322",{"type":57,"coordinates":199},[200,201],-84.38798,33.749,{"lat":201,"lon":200},[204,208],{"name":205,"role":65,"phone":206,"phoneExt":35,"email":207},"Winship Referrals","404-778-1900","winship.referrals@emoryhealthcare.org",{"name":209,"role":46,"phone":35,"phoneExt":35,"email":35},"Jennifer Scalici, MD",{"facility":211,"status":50,"city":212,"state":213,"zip":214,"country":54,"countryCode":55,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"Indiana University Simon Comprehensive Cancer Center","Indianapolis","Indiana","46202",{"type":57,"coordinates":216},[217,218],-86.15804,39.76838,{"lat":218,"lon":217},[221,225],{"name":222,"role":65,"phone":223,"phoneExt":35,"email":224},"Cheri West, RN","317-278-3021","chawest@iu.edu",{"name":226,"role":46,"phone":35,"phoneExt":35,"email":35},"Jessica E. Parker, MD",{"facility":228,"status":50,"city":229,"state":230,"zip":231,"country":54,"countryCode":55,"cosmosGeoPoint":232,"geoPoint":236,"contacts":237},"Holy Cross Hospital","Silver Spring","Maryland","20910",{"type":57,"coordinates":233},[234,235],-77.02609,38.99067,{"lat":235,"lon":234},[238,242,244],{"name":239,"role":65,"phone":240,"phoneExt":35,"email":241},"Lyudmila Igorevna Kalnitskaya, MBA, MS","301-754-7552","kalnitsl@holycrosshealth.org",{"name":243,"role":46,"phone":35,"phoneExt":35,"email":35},"Frederick D Min, MD",{"name":245,"role":125,"phone":35,"phoneExt":35,"email":35},"Jasmine Ebott, MD",{"facility":247,"status":50,"city":248,"state":249,"zip":250,"country":54,"countryCode":55,"cosmosGeoPoint":251,"geoPoint":255,"contacts":256},"University of Michigan","Ann Arbor","Michigan","48109",{"type":57,"coordinates":252},[253,254],-83.74088,42.27756,{"lat":254,"lon":253},[257,261,265],{"name":258,"role":65,"phone":259,"phoneExt":35,"email":260},"Zhen Zhou","917-912-3028","zhenniz@med.umich.edu",{"name":262,"role":65,"phone":263,"phoneExt":35,"email":264},"Munira Hussain","734-936-8349","hussain@med.umich.edu",{"name":266,"role":46,"phone":35,"phoneExt":35,"email":35},"Jean Siedel, MD",{"facility":268,"status":50,"city":269,"state":249,"zip":270,"country":54,"countryCode":55,"cosmosGeoPoint":271,"geoPoint":275,"contacts":276},"Karmanos Cancer Institute","Detroit","48201",{"type":57,"coordinates":272},[273,274],-83.04575,42.33143,{"lat":274,"lon":273},[277,281],{"name":278,"role":65,"phone":279,"phoneExt":35,"email":280},"Elizabeth Linnik","313-576-9764","linnike@karmanos.org",{"name":282,"role":46,"phone":35,"phoneExt":35,"email":35},"Robert Morris, MD",{"facility":284,"status":50,"city":285,"state":286,"zip":287,"country":54,"countryCode":55,"cosmosGeoPoint":288,"geoPoint":292,"contacts":293},"Washington University School of Medicine","St Louis","Missouri","63110",{"type":57,"coordinates":289},[290,291],-90.19789,38.62727,{"lat":291,"lon":290},[294,298],{"name":295,"role":65,"phone":296,"phoneExt":35,"email":297},"Tiara Redrick","314-362-1705","tredrick@wustl.edu",{"name":299,"role":46,"phone":35,"phoneExt":35,"email":35},"Premal Thaker, MD",{"facility":301,"status":50,"city":285,"state":286,"zip":302,"country":54,"countryCode":55,"cosmosGeoPoint":303,"geoPoint":305,"contacts":306},"Mercy Hospital St. Louis","63141",{"type":57,"coordinates":304},[290,291],{"lat":291,"lon":290},[307,311],{"name":308,"role":65,"phone":309,"phoneExt":35,"email":310},"Enguday Teshome","314-251-0742","Enguday.teshome@mercy.net",{"name":312,"role":46,"phone":35,"phoneExt":35,"email":35},"Madhavi Manyam, MD",{"facility":314,"status":50,"city":315,"state":316,"zip":317,"country":54,"countryCode":55,"cosmosGeoPoint":318,"geoPoint":322,"contacts":323},"Women's Cancer Center of Nevada","Las Vegas","Nevada","89106",{"type":57,"coordinates":319},[320,321],-115.13722,36.17497,{"lat":321,"lon":320},[324,328,331],{"name":325,"role":65,"phone":326,"phoneExt":35,"email":327},"Thania Escamilla","702-851-4672","tescamilla@wccenter.com",{"name":329,"role":65,"phone":326,"phoneExt":35,"email":330},"Jacky Amador","Jamador@wccenter.com",{"name":332,"role":46,"phone":35,"phoneExt":35,"email":35},"Nicola M. Spirtos, MD",{"facility":334,"status":50,"city":335,"state":316,"zip":336,"country":54,"countryCode":55,"cosmosGeoPoint":337,"geoPoint":341,"contacts":342},"Center of Hope","Reno","89511",{"type":57,"coordinates":338},[339,340],-119.8138,39.52963,{"lat":340,"lon":339},[343,347],{"name":344,"role":65,"phone":345,"phoneExt":35,"email":346},"Peter Lim, MD","775-327-4611","Plim@cohreno.com",{"name":344,"role":46,"phone":35,"phoneExt":35,"email":35},{"facility":349,"status":50,"city":350,"state":351,"zip":352,"country":54,"countryCode":55,"cosmosGeoPoint":353,"geoPoint":357,"contacts":358},"Stony Brook Cancer Center","Stony Brook","New York","11794",{"type":57,"coordinates":354},[355,356],-73.14094,40.92565,{"lat":356,"lon":355},[359,363,367],{"name":360,"role":65,"phone":361,"phoneExt":35,"email":362},"Latrice Tribble-Jones","631-216-2988","latrice.tribble@stonybrookmedicine.edu",{"name":364,"role":65,"phone":365,"phoneExt":35,"email":366},"Anu John, MSN, RN","631-972-0147","Anu.John@stonybrookmedicine.edu",{"name":368,"role":46,"phone":35,"phoneExt":35,"email":35},"Gabrielle Gossner, MD",{"facility":370,"status":50,"city":371,"state":372,"zip":373,"country":54,"countryCode":55,"cosmosGeoPoint":374,"geoPoint":378,"contacts":379},"Levine Cancer Institute","Charlotte","North Carolina","28204",{"type":57,"coordinates":375},[376,377],-80.84313,35.22709,{"lat":377,"lon":376},[380,384],{"name":381,"role":65,"phone":382,"phoneExt":35,"email":383},"Leah Wilson","980-442-2333","Leah.J.Wilson@atriumhealth.org",{"name":385,"role":46,"phone":35,"phoneExt":35,"email":35},"Erin K Crane, MD",{"facility":387,"status":50,"city":388,"state":372,"zip":389,"country":54,"countryCode":55,"cosmosGeoPoint":390,"geoPoint":394,"contacts":395},"East Carolina University","Greenville","27834",{"type":57,"coordinates":391},[392,393],-77.36635,35.61266,{"lat":393,"lon":392},[396,400],{"name":397,"role":65,"phone":398,"phoneExt":35,"email":399},"Grainger Lanneau, MD","252-816-2743","Grainger.Lanneau@ecuhealth.org",{"name":397,"role":46,"phone":35,"phoneExt":35,"email":35},{"facility":402,"status":50,"city":403,"state":404,"zip":405,"country":54,"countryCode":55,"cosmosGeoPoint":406,"geoPoint":410,"contacts":411},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":57,"coordinates":407},[408,409],-81.69541,41.4995,{"lat":409,"lon":408},[412,416],{"name":413,"role":65,"phone":414,"phoneExt":35,"email":415},"Barbara Bittel","216-390-2456","Bittelb@ccf.org",{"name":417,"role":46,"phone":35,"phoneExt":35,"email":35},"Peter Rose, MD",{"facility":419,"status":50,"city":420,"state":404,"zip":421,"country":54,"countryCode":55,"cosmosGeoPoint":422,"geoPoint":426,"contacts":427},"OhioHealth Research Institute","Columbus","43214",{"type":57,"coordinates":423},[424,425],-82.99879,39.96118,{"lat":425,"lon":424},[428,432],{"name":429,"role":65,"phone":430,"phoneExt":35,"email":431},"Jennifer Sexton","614-788-3860","Jennifer.Sexton@ohiohealth.com",{"name":433,"role":46,"phone":35,"phoneExt":35,"email":35},"Aine Clements, MD",{"facility":435,"status":50,"city":436,"state":404,"zip":437,"country":54,"countryCode":55,"cosmosGeoPoint":438,"geoPoint":442,"contacts":443},"Kettering Health","Kettering","45429",{"type":57,"coordinates":439},[440,441],-84.16883,39.6895,{"lat":441,"lon":440},[444,448],{"name":445,"role":65,"phone":446,"phoneExt":35,"email":447},"Daniel Geyer","937-395-6017","daniel.geyer@ketteringhealth.org",{"name":449,"role":46,"phone":35,"phoneExt":35,"email":35},"Thomas J. Reid, MD",{"facility":451,"status":50,"city":452,"state":404,"zip":453,"country":54,"countryCode":55,"cosmosGeoPoint":454,"geoPoint":458,"contacts":459},"ProMedica Flower Hospital","Sylvania","43560",{"type":57,"coordinates":455},[456,457],-83.71299,41.71894,{"lat":457,"lon":456},[460,464,468],{"name":461,"role":65,"phone":462,"phoneExt":35,"email":463},"Carissa Jock","419-824-1011","Carissa.jock@promedica.org",{"name":465,"role":65,"phone":466,"phoneExt":35,"email":467},"Julie Moon","419-824-8812","Julie.moon@promedica.org",{"name":469,"role":46,"phone":35,"phoneExt":35,"email":35},"Adam Walter, MD",{"facility":471,"status":50,"city":472,"state":473,"zip":474,"country":54,"countryCode":55,"cosmosGeoPoint":475,"geoPoint":479,"contacts":480},"Oklahoma University Health Stephenson Cancer Center","Oklahoma City","Oklahoma","73104",{"type":57,"coordinates":476},[477,478],-97.51643,35.46756,{"lat":478,"lon":477},[481,486,491],{"name":482,"role":65,"phone":483,"phoneExt":484,"email":485},"Nikolas Williams","405-271-8001","18001","nikolas-williams@ou.edu",{"name":487,"role":65,"phone":488,"phoneExt":489,"email":490},"Debra Richardson, MD","405-271-1112","31839","debra-richardson@ou.edu",{"name":487,"role":46,"phone":35,"phoneExt":35,"email":35},{"facility":493,"status":50,"city":494,"state":495,"zip":496,"country":54,"countryCode":55,"cosmosGeoPoint":497,"geoPoint":501,"contacts":502},"AHN West Penn Hospital","Pittsburgh","Pennsylvania","15224",{"type":57,"coordinates":498},[499,500],-79.99589,40.44062,{"lat":500,"lon":499},[503,507,511],{"name":504,"role":65,"phone":505,"phoneExt":35,"email":506},"Sarah Crafton, MD","412-578-1116","Sarah.Crafton@ahn.org",{"name":508,"role":65,"phone":509,"phoneExt":35,"email":510},"AHN Clinical Trial","412-359-3731","clinicaltrials@ahn.org",{"name":504,"role":46,"phone":35,"phoneExt":35,"email":35},{"facility":513,"status":50,"city":514,"state":515,"zip":516,"country":54,"countryCode":55,"cosmosGeoPoint":517,"geoPoint":521,"contacts":522},"Hollings Cancer Center","Charleston","South Carolina","29425",{"type":57,"coordinates":518},[519,520],-79.93275,32.77632,{"lat":520,"lon":519},[523,527],{"name":524,"role":65,"phone":525,"phoneExt":35,"email":526},"Crystal Knox","843-792-2803","knoxc@musc.edu",{"name":528,"role":46,"phone":35,"phoneExt":35,"email":35},"Brian Orr, MD",{"facility":530,"status":50,"city":531,"state":532,"zip":533,"country":54,"countryCode":55,"cosmosGeoPoint":534,"geoPoint":538,"contacts":539},"Erlanger Health, Inc.","Chattanooga","Tennessee","37403",{"type":57,"coordinates":535},[536,537],-85.30968,35.04563,{"lat":537,"lon":536},[540,544],{"name":541,"role":65,"phone":542,"phoneExt":35,"email":543},"Lorraine Christensen","423-778-3902","Lorraine.Christensen@erlanger.org",{"name":545,"role":46,"phone":35,"phoneExt":35,"email":35},"Stephen DePasquale, MD",{"facility":547,"status":50,"city":548,"state":549,"zip":550,"country":54,"countryCode":55,"cosmosGeoPoint":551,"geoPoint":555,"contacts":556},"Baylor College of Medicine","Houston","Texas","77030",{"type":57,"coordinates":552},[553,554],-95.36327,29.76328,{"lat":554,"lon":553},[557,561],{"name":558,"role":65,"phone":559,"phoneExt":35,"email":560},"Jan Sunde, MD","832-957-6500","jan.sunde@bcm.edu",{"name":558,"role":46,"phone":35,"phoneExt":35,"email":35},{"facility":563,"status":50,"city":548,"state":549,"zip":550,"country":54,"countryCode":55,"cosmosGeoPoint":564,"geoPoint":566,"contacts":567},"University of Texas Science Center at Houston, McGovern Medical School",{"type":57,"coordinates":565},[553,554],{"lat":554,"lon":553},[568,572],{"name":569,"role":65,"phone":570,"phoneExt":35,"email":571},"Gabrielle Hayes","713-704-4137","gabrielle.a.hayes@uth.tmc.edu",{"name":573,"role":46,"phone":35,"phoneExt":35,"email":35},"Joseph Lucci, III, MD",{"facility":575,"status":50,"city":576,"state":577,"zip":578,"country":54,"countryCode":55,"cosmosGeoPoint":579,"geoPoint":583,"contacts":584},"Providence Sacred Heart Medical Center & Children's Hospital","Spokane","Washington","99204",{"type":57,"coordinates":580},[581,582],-117.42908,47.65966,{"lat":582,"lon":581},[585,589],{"name":586,"role":65,"phone":587,"phoneExt":35,"email":588},"Jodie Mactagone, CRC","509-474-3821","Jodie.mactagone@providence.org",{"name":590,"role":46,"phone":35,"phoneExt":35,"email":35},"Melanie Bergman, MD",{"type":592,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR",[594],{"name":595,"class":596},"GOG Foundation","NETWORK","100460887","phase-3-efficacy--safety-of-olvi-vec-and-platinum-doublet--bevacizumab-compared-to-physicians-choice-of-chemotherapy-and-bevacizumab-in-platinum-resistantrefractory-ovarian-cancer-prroc-onprime-gog-3076-100460887",false,"NCT05281471","Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant\u002FRefractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant\u002FRefractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","Inclusion Criteria:\n\n* Histologically confirmed (from prior treatment) non-resectable ovarian, fallopian tube or primary peritoneal cancer.\n* High-grade serous \\[including malignant mixed Mullerian tumor (MMMT) with metastasis that contains high-grade epithelial carcinoma, FIGO grades 2 \\& 3 allowed\\], endometrioid, or clear-cell ovarian cancer.\n* Performance status ECOG of 0 or 1.\n* Life expectancy of at least 6 months.\n* Received a minimum of 3 prior lines (including the 1st line) of systemic therapy with no maximal limit.\n* Platinum-resistant or -refractory disease based on platinum-free interval (PFI) from the last dose of the most recent. platinum-based line of therapy (must have received a minimum of 2 doses of platinum in that line) to subsequent disease progression based on radiological assessment. Platinum-refractory: PFI of \\\u003C 1 month (including disease progression while on platinum-based therapy). Platinum-resistant: PFI of 1-6 months.\n* Received prior bevacizumab (or biosimilar) treatment.\n* No contraindication to receive carboplatin, cisplatin or bevacizumab (or biosimilar).\n* Have disease progression after last prior line of therapy based on radiological assessment prior to randomization.\n* At least 1 measurable target lesion per RECIST 1.1 based on abdominal\u002Fpelvis imaging scan at screening.\n* Evidence by CT and\u002For PET scans or physical exam of abdominal\u002Fpelvis region likely having disease in the peritoneal cavity (i.e., peritoneal carcinomatosis).\n* Adequate renal, hepatic, bone marrow function, adequate coagulation tests, adequate immune function by lymphocyte count.\n\nExclusion Criteria:\n\n* Tumors of mucinous, low-grade serous, squamous cell, small cell neuroendocrine subtypes, MMMT tumors absent an epithelial component on recent biopsy, or non-epithelial ovarian cancers (e.g., germ cell tumors, Sex-cord tumors).\n* Bowel obstruction within last 3 months prior to screening.\n* Active urinary tract infection, pneumonia, other systemic infections.\n* Active gastrointestinal bleeding.\n* Known current central nervous system (CNS) metastasis.\n* Inflammatory diseases of the bowel.\n* History of HIV infection.\n* Active hepatitis B virus or hepatitis C virus within 4 weeks prior to study.\n* History of thromboembolic event within the prior 3 months.\n* Contraindications for intraperitoneal (IP) catheter placement: Bowel obstruction with distended abdomen, rigid abdomen with bulky anterior wall carcinomatosis, abdominal wall hernia mesh that precludes laparoscopic entry to abdomen.\n* Clinically significant cardiac disease at screening (New York Heart Association Class III\u002FIV).\n* Acute cerebrovascular event(s) such as cerebrovascular accident (CVA) or transient ischemic attack (TIA) in previous 6 months.\n* Oxygen saturation \\\u003C90%.\n* Received prior virus-based gene therapy or therapy with cytolytic virus of any type.\n* Receiving concurrent antiviral agent.\n* Prior malignancy of other histology active within previous 3 years except for locally curable cancers apparently cured such as basal\u002Fsquamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast, any other stage I\u002FII local malignancies.\n* Received chemotherapy, radiotherapy, other anti-cancer biologic therapies within 4 weeks prior to planned treatment.\n* Underwent surgery within 4 weeks, or have insufficient recovery from surgical-related trauma or wound healing, prior to first study treatment in either Arm.\n* Receiving immunosuppressive therapy or steroids (except acute concurrent corticosteroid of no more than 20 mg per day for medical management with prednisolone equivalent.\n* Symptomatic malignant ascites or pleural effusions defined as rapidly progressive ascites with abdominal distension and gastrointestinal dysfunction, pleural effusions with respiratory difficulties requiring frequent paracentesis \\> once every 14 days.\n* Known hypersensitivity to gentamicin.","FEMALE","18 Years",{"count":607,"type":608},186,"ESTIMATED","INTERVENTIONAL",[611],"PHASE3","The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant\u002Frefractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant\u002Frefractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.",[614,615,616,617,618,619,620],"Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer","High-grade Serous Ovarian Cancer","Endometrioid Ovarian Cancer","Ovarian Clear Cell Carcinoma",[25,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642],"GL-ONC1","GLV-1h68","oncolytic virus","virotherapy","viral therapy","immunotherapy","immunochemotherapy","combination therapy","vaccinia virus","ovarian cancer","fallopian tube cancer","primary peritoneal cancer","platinum resistant","platinum refractory","recurrent ovarian cancer","platinum resensitization","chemoresistance","heavily pre-treated","immune activation","reversal of platinum resistance or refractoriness","resensitize","2026-03-16",{"date":645,"type":646},"2026-03-18","ACTUAL",{"date":648,"type":646},"2022-08-31",{"date":650,"type":608},"2026-10",{"name":5,"class":6},31]